Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Temozolomide in Acute Myeloid Leukemia Patient Age >= 60 Yrs & Poor Risk/Refractory Disease
This study has been completed.
Study NCT00611247   Information provided by Stanford University

First Received on January 25, 2008.   Last Updated on July 16, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia, Myeloid
Additional conditions recognized in this trial
Leukemia
Leukemia, Myeloid, Acute
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Temozolomide
Additional drug interventions recognized in this trial
Dacarbazine
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Bruno C. Medeiros
Schering-Plough


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services